120629-58-5

Basic information

• Product Name: Benzamide, 3-amino-4-hydroxy- (9CI)
• Synonyms: Benzamide, 3-amino-4-hydroxy- (9CI)
• CAS NO: 120629-58-5
• Molecular Formula: C₇H₈N₂O₂
• Molecular Weight: 152.15062
• Product Categories: AMIDE
• Mol File: 120629-58-5.mol

Chemical Properties

• Boiling Point: 337.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.397±0.06 g/cm3(Predicted)
• PKA: 8.44±0.18(Predicted)
• CAS DataBase Reference: Benzamide, 3-amino-4-hydroxy- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 3-amino-4-hydroxy- (9CI)(120629-58-5)
• EPA Substance Registry System: Benzamide, 3-amino-4-hydroxy- (9CI)(120629-58-5)

Safety Data

• Hazardous Substances Data: 120629-58-5(Hazardous Substances Data)

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 1571-72-8 3-amino-4-hydroxybenzoic acid 
• 616-82-0 3-nitro-4-hydroxybenzoic acid 
• 99-42-3 methyl (4-hydroxy-3-nitro)benzoate 
• 70382-03-5 3-nitro-4-hydroxybenzamide 

Downstream Products

• 1421257-26-2 C₂₁H₂₈N₄O₄ 
• 1377579-27-5 3-(2',4'-Dimethyl-[4,5']bithiazolyl-2-ylamino)-4-(2,2,2-trifluoro-ethoxy)-benzamide 
• 1377579-23-1 3-(2',4'-Dimethyl-[4,5']bithiazolyl-2-ylamino)-4-propoxy-benzamide 
• 1377581-97-9 3-(2',4'-dimethyl-[4,5']bithiazolyl-2-ylamino)-4-hydroxy-benzamide 
• 1377581-95-7 4-hydroxy-3-thioureido-benzamide 
• 1134198-24-5 4-hydroxy-3-{[1-(trans-1-methyl-4-{[2-(methyloxy)ethyl]oxy}cyclohexyl)-4-piperidinyl]amino}benzamide 
• 1134198-23-4 3-({1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}amino)-4-hydroxybenzamide 

Relevant articles and documents

4-Hydroxy-3-Nitrosobenzamide and Its Ferrous Chelate from Streptomyces murayamaensis

Two new colored metabolites of Streptomyces murayamaensis have been isolated and characterized as 4-hydroxy-3-nitrosobenzamide and its ferrous chelate.These structures have been confirmed by synthesis via a modified Baudisch reaction.A sample of 3-amino-4

NOVEL LOW-MOLECULAR-COMPOUND FOR IMPROVING PRODUCTION, MAINTENANCE AND PROLIFERATION OF PLURIPOTENT STEM CELLS, COMPOSITION COMPRISING THE SAME, AND CULTURE METHOD

According to the present invention, when the novel low-molecular-weight compound RSC-133 is added in a culture process for producing reprogrammed pluripotent stem cells from human differentiated cells, it can increase the efficiency of reprogramming and c

NOVEL LOW-MOLECULE COMPOUND FOR PROMOTING PLURIPOTENT STEM CELL GENERATION, MAINTENANCE, AND PROLIFERATION, AND COMPOSITION AND CULTURING METHOD CONTAINING SAME

According to the present invention, when the novel low-molecular-weight compound RSC-133 is added in a culture process for producing reprogrammed pluripotent stem cells from human differentiated cells, it can increase the efficiency of reprogramming and c

BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I) or a salt thereof are provided: wherein R4, R5, R6, Q, A, Y and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders, cognitive impairments and Alzheimer's Disease are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

Nonpeptide inhibitors of measles virus entry

Measles virus (MV) is one of the most infectious pathogens known. Despite the existence of a vaccine, over 500 000 deaths/year result from MV or associated complications. Anti-measles compounds could conceivably reverse these statistics. Previously, we described a homology model of the MV fusion protein trimer and a putative binding site near the head-neck region. The resulting model permitted the identification of two nonpeptidic entry inhibitors. Here, we present the design, synthesis, and bioevaluation of several series of fusion inhibitors and describe their structure-activity relationships (SAR). Five simply substituted anilides show low-μM blockade of the MV, one of which (AS-48) exhibits IC50 = 0.6-3.0 μM across a panel of wild-type MV strains found in the field. Molecular field topology analysis (MFTA), a 2D QSAR approach based on local molecular properties (atomic charges, hydrogen-bonding capacity and local lipophilicity), applied to the anilide series suggests structural modifications to improve potency.

Amino-benzoic acids and derivatives, and methods of use

The present invention relates to compounds, compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with a carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.

Methods for glycosylation inhibition using amino-benzoic acids and derivatives

The present invention relates to compounds, compositions and methods for inhibiting nonenzymatic cross-linking (protein aging). Accordingly, a composition is disclosed which comprises an agent capable of inhibiting the formation of advanced glycosylation endproducts of target proteins by reacting with a carbonyl moiety of the early glycosylation product of such target proteins formed by their initial glycosylation. The method comprises contacting the target protein with the composition. Both industrial and therapeutic applications for the invention are envisioned, as food spoilage and animal protein aging can be treated.